TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: Four-week Continuous Abstinence From Cigarette Smoking (Study week 8 thru week 11)
B: Continuous abstinence (Russell Standard) (Six months post quit date)
C: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed (6 months post quit date)
D: Continuous smoking abstinence rate (Weeks 9 to 12)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: Change in smoking status over time (At 12, 26, and 52 weeks following start of treatment)
B: Smoking Abstinence (3 months); Smoking Abstinence (6 months); Smoking Abstinence (12 months)
C: Biochemically verified 7 day point prevalence abstinence from smoking.
D: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed (6 months post quit date)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: Composite criterion : fatal and non-fatal cardiovascular or cerebrovascular events (During all the study)
B: Prolonged Abstinence (7 weeks, 6 months and 12 months)
C: Self-reported, Prolonged Abstinence From Smoking Between a Quit Date and 6 Months Afterwards. (6 months from participant's quit date)
D: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed (6 months post quit date)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: Participants Abstinent From Cigarettes (Two years)
B: 7-day smoking abstinence (7 days); 6-month smoking abstinence (6 months); cost-effectiveness (6 months)
C: Continuous Abstinence From Smoking at Ten Weeks Post-quit (May 2009)
D: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed (6 months post quit date)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: 4-week continuous quit rate (CQR) at Weeks 4-7 and 9-12 .
B: to assess the continuous abstinence from tobacco smoking at every visit during the last four weeks of treatment through direct inquiry of patients; exhaled carbon monoxide testing; and plasma cotinine measurements
C: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed (6 months post quit date)
D: Proportion of Daily Cigarettes Smoked in the 4 Hours After Receiving Methadone Dose (7 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: Percentage of Participants With Carbon Monoxide (CO) Confirmed 10-Week Continuous Abstinence (CA) From Smoking (Week 15 - 24)
B: 7 day point prevalence of cigarette abstinence; measured at Week 13 and on a weekly basis (Weekly, and 13 weeks after beginning study medication (Week 13).)
C: Percent Treatment Sessions Attended (52 weeks)
D: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed (6 months post quit date)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: Prolonged Smoking Abstinence Rates at 12 Weeks in Cigarettes Smokers. (3 months); Point Prevalence Abstinence at 3 Months. (3 months)
B: Success rates and safety at week 24 in the varenicline vs placebo. Success rates will be defined as the Continuous Quit Rate since last visit. Maintain abstinence during this period of time with end-expiratory exhaled CO measurements ≤ 10 ppm. (week 24)
C: 7-day Point Prevalence Abstinence From Smoking at 6 Months (6 months)
D: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed (6 months post quit date)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacotherapies: Efficacy, Mechanisms and Algorithms
Brief Summary: The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.


Options:
A: 7-day Point Prevalence Smokeless Tobacco Abstinence Biochemically Confirmed With Urine Cotinine at the End of 12 Weeks of Treatment. (At the end of treatment (12 weeks))
B: 7-day Prevalence of Abstinence From Cigarette Smoking at 12 Weeks (12 weeks); 7 Day Prevalence of Abstinence From Cigarette Smoking at 24 Weeks (24 weeks)
C: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed (6 months post quit date)
D: Smoking Status (at week 48)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Childhood Depression: Remission and Relapse
Brief Summary: This study will determine the optimal length of continuation treatment with fluoxetine for children and adolescents with major depressive disorder, as well as the factors that may contribute to positive response during acute and continuation treatment.


Options:
A: Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score (From Baseline to week 8)
B: Change From Baseline in the Children's Depression Rating Scale Revised (CDRS-R) Total Score at Week 8 (Baseline, Week 8)
C: Measured throughout the study: Relapse; Time to relapse
D: The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS SR versus subjects receiving placebo.

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of Stepping Stones Behavioural Intervention for HIV
Brief Summary: This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural South African communities.


Options:
A: Mental health state (anxiety) (Before intervention begins and through intervention completion on average of 15 days); Mental health state (Depression) (Before intervention begins and through intervention completion on average of 15 days)
B: HIV sero-incidence (24 months post-baseline)
C: Number of significantly improved child and maternal outcomes (2 Years)
D: Change in Reach (implementation) (Change from Baseline in Reach at 12 months); Cost (Cost of implementing each arm will be calculated through study completion, an average of 2 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of Stepping Stones Behavioural Intervention for HIV
Brief Summary: This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural South African communities.


Options:
A: depression (On completion of intervention and six months post-intervention)
B: HIV sero-incidence (24 months post-baseline)
C: Discussion of family psychosocial problem; Referral of family psychosocial problem; Contacting community resources
D: Quality of Life, Physical Health Composite (at one-year follow-up); Quality of Life, Mental Health Composite (past 30 days)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of Stepping Stones Behavioural Intervention for HIV
Brief Summary: This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural South African communities.


Options:
A: HIV sero-incidence (24 months post-baseline)
B: Self-reported proportion of condom-protected sexual intercourse (Measured at Month 12); Occurrence of STDs (chlamydia, gonorrhea, and trichomonas) (Measured at Month 12)
C: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms (Throughout study); All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms (Throughout study)
D: Frequency of unprotected sexual acts with nonspousal partners (Measured at baseline and Years 1 and 2); Overall observed incidence of sexually transmitted diseases (STDs) (e.g., chlamydia, gonorrhea, syphilis, trichomonas, HIV, or herpes simplex virus-2), as detected by biological specimens (Measured at baseline and Years 1 and 2)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of Stepping Stones Behavioural Intervention for HIV
Brief Summary: This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural South African communities.


Options:
A: HIV sero-incidence (24 months post-baseline)
B: Re-infection with a non-viral sexually transmitted infection (1 year)
C: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA Negative and Seronegative at Baseline or Overall (Any Serostatus at Baseline) (Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post-dose 3); Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA Negative and Seronegative at Baseline or Overall (Any Serostatus at Baseline) (at Month 48)
D: Sexually transmitted disease (Measured at 2nd and 3rd trimesters and Months 6 and 12 postpartum); Rapid repeat pregnancy (Measured at Month 12 postpartum); Sexual risk behavior (Measured at 2nd and 3rd trimesters and Months 6 and 12 postpartum); Perinatal outcomes (e.g., birth weight, gestational age) (Measured at Months 6 and 12 postpartum)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of Stepping Stones Behavioural Intervention for HIV
Brief Summary: This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural South African communities.


Options:
A: Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat Population (42 Months); Vaccine Efficacy as Determined by Acquisition of Infection in the Per-protocol Population (42 Months); Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the MITT Population (42 months); Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the Per Protocol Population (42 months)
B: HIV sero-incidence (24 months post-baseline)
C: HIV acquisition; safety of circumcision
D: HIV incidence (2 years); surgical complications (2 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of Stepping Stones Behavioural Intervention for HIV
Brief Summary: This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural South African communities.


Options:
A: Unprotected vaginal and anal sex (Baseline); Unprotected vaginal and anal sex (6 month follow-up); Unprotected vaginal and anal sex (12-month follow-up)
B: rates of STIs (Baseline, 6 and 12 months); computer-assisted survey results (baseline, 1 week, 3, 6, & 12 months); - score on self-report of frequency of risky sexual and substance use behaviors (baseline, 1 week, 3, 6, & 12 months)
C: HIV sero-incidence (24 months post-baseline)
D: HIV-1 seroincidence; HSV2 seroprevalence

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of Stepping Stones Behavioural Intervention for HIV
Brief Summary: This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural South African communities.


Options:
A: Sexually Transmitted Infections (18 months); Schooling (12 months/24 months)
B: HIV sero-incidence (24 months post-baseline)
C: Understanding of key findings (30 minutes)
D: Number of Participants Completing Secondary School [Sit 10th Standard Exam] (May-August 2016 (cohort one) and May-August 2017 (cohort two)); Number of Participants Married [by Trial End Line] (May-August 2016 (cohort one) and May-August 2017 (cohort two))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of Stepping Stones Behavioural Intervention for HIV
Brief Summary: This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural South African communities.


Options:
A: Composite score of essential aspects of family planning/HTC service provision calculated from VHTs' responses to survey questions (10 days)
B: HIV sero-incidence (24 months post-baseline)
C: Sequence-verified HIV-transmission from index to partner participant (March 2009)
D: pregnancy

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT of Stepping Stones Behavioural Intervention for HIV
Brief Summary: This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural South African communities.


Options:
A: Contraceptive use at time of last sexual intercourse (18 months)
B: rates of STIs (Baseline, 6 and 12 months); computer-assisted survey results (baseline, 1 week, 3, 6, & 12 months); - score on self-report of frequency of risky sexual and substance use behaviors (baseline, 1 week, 3, 6, & 12 months)
C: HIV-1 seroincidence; HSV2 seroprevalence
D: HIV sero-incidence (24 months post-baseline)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase
Brief Summary: This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.


Options:
A: Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core) (Month 6 (Core)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12 (Month 12 (extension)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60 (Month 60 (extension)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study (Last observation (Up to 80 months in average))
B: Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression (Day 1 to 12 months); Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial Regression (Day 1 up to 6.5 years)
C: Annualized Relapse Rate (ARR) at 1 Year (1 Year)
D: Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain (Week 12 to Week 24)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase
Brief Summary: This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.


Options:
A: Number of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6 (Month 3 and Month 6)
B: Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24))
C: Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core) (Month 6 (Core)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12 (Month 12 (extension)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60 (Month 60 (extension)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study (Last observation (Up to 80 months in average))
D: Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24 (24 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase
Brief Summary: This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.


Options:
A: Annualized Relapse Rate (2 years)
B: Number of new or enlarged gadolinium contrast enhancing lesions (Gd-CELs) on monthly brain MRIs collected between Weeks 8 to 24 in daclizumab- vs. placebo-treated patients
C: Time to First Relapse (Baseline up to 96 weeks)
D: Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core) (Month 6 (Core)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12 (Month 12 (extension)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60 (Month 60 (extension)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study (Last observation (Up to 80 months in average))

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase
Brief Summary: This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.


Options:
A: Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core) (Month 6 (Core)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12 (Month 12 (extension)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60 (Month 60 (extension)); Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study (Last observation (Up to 80 months in average))
B: Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period (Up to Month 24)
C: Time to Confirmed Disease Progression (CDP) (96 weeks (from Screening to Week 96, and at least 12 weeks after initial progression)); Percentage of Participants With CDP (96 weeks (from Screening to Week 96, and at least 12 weeks after initial progression))
D: Dose Responsiveness of BAF312 Based on the Number of Combined Unique Active MRI Lesions (CUAL) (3 months of treatment)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.


Options:
A: HbA1c (after 26 weeks of treatment)
B: Change From Baseline in HbA1c at Week 52 (Baseline and Week 52)
C: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks)
D: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.


Options:
A: HbA1c (after 26 weeks of treatment)
B: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26)
C: HbA1c (after 26 weeks of treatment)
D: N/A

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.


Options:
A: HbA1c (after 26 weeks of treatment)
B: HbA1c (after 26 weeks of treatment)
C: Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (week 0, week 52); Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 104 (week 0, week 104); Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156 (week 0, week 156)
D: Change in HbA1c From Baseline to Week 30 (Day -3, Week 30); Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose) (Week 22)

Answer: B